Stay updated with breaking news from Ichida Stem Cell Lab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Topline clinical secondary efficacy results and primary safety endpoints from Phase 2b ALS trial expected in early December 2023Patients who completed the 18-month PARADIGM trial, including the...
Phase 2b ALS topline results expected December 2023 CAMBRIDGE, Mass., Oct. 17, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. , a company developing treatments for severe neurodegenerative...
In collaboration with the University of Southern California's Ichida Stem Cell Lab, PrimeC was shown to significantly increase survival rate of induced motor neurons in an in vitro study utilizing...